Insulin-like Growth Factor Receptor signaling

**Figure 1:**
A - IGF-1R signal point blocked by a small molecule TKI.
B - IGF1 Ligand docked and IGF-1R Receptor in normal “On” mode.
C - IGF1 Ligand docking site blocked by a Monoclonal Antibody
Small molecules can have collateral targets that can either enhance tumor inhibition and/or caused unwanted side-effects. Most IGF-1R inhibitors in trials today are monoclonal antibodies. The exceptions are OSI-906 and XL228. When drugs are assigned a generic name you can usually tell which are monoclonal antibodies because they all have the suffix ‘mab’. Figitumumab (CP-751,871) and Cixutumumab (IMC-A12) are two examples.

One caution when evaluating IGF-1R trials is to be aware that some trials preclude the use of any prior IGF-1R therapy (BIIB022 and AMG 479). You may want to take this into account in optimizing your trial plan.

In this months report we have included eleven new Phase 1 trials of IGF-1R inhibitors. Two of these will accept patients younger than eighteen. This months report also reflects the termination of the imatinib plus RAD001 trial that was accruing at nine sites in Germany.

**Phase 1 Options for Advanced Wild Type GIST:**

**IGF-1R Inhibitors**

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Timeline 2008</th>
<th>Timeline 2009</th>
<th>Timeline 2010</th>
<th>Timeline 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMG479 + AMG655 (TNF)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIIB022*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMS-754807</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CP,751-871 + Sunitinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMC-A12 + Temsirolimus (mTOR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMC-A12 + Temsirolimus (mTOR) Ages 1-21 yrs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEDI-573</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MK-0646 + Ridaforolimus (mTOR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSI-906</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R1507 Ages 2-17 yrs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XL228</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Exclude prior IGF-1R inhibitor therapy
Note: Trials are first grouped together by treatment phase. For example, the first grouping lists 2 trials that are open to patients in all treatment stages. Each trial description also lists the treatment stage under the "Stage" heading. Trials that are specifically for GIST are listed first. Trials are then sorted by phase (in descending order) and then by drug name. Trial sites are sorted by country, state and then city.

<table>
<thead>
<tr>
<th>Treatment Stage: All</th>
<th>Treatment Stage: First-line</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imatinib</strong></td>
<td><strong>Imatinib + Bevacizumab</strong></td>
</tr>
<tr>
<td><em>Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor</em></td>
<td><em>Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor</em></td>
</tr>
<tr>
<td><strong>Phase:</strong> 2</td>
<td><strong>Phase:</strong> 3</td>
</tr>
<tr>
<td><strong>Stage:</strong> All</td>
<td><strong>Stage:</strong> First-line</td>
</tr>
<tr>
<td><strong>Conditions:</strong> Gastrointestinal Stromal Tumor</td>
<td><strong>Conditions:</strong> Gastrointestinal Stromal Tumor</td>
</tr>
<tr>
<td><strong>Drug Type:</strong> KIT/PDGFRA inhibitor</td>
<td><strong>Drug Type:</strong> KIT/PDGFRA inhibitor + VEGF inhibitor (antibody)</td>
</tr>
<tr>
<td><strong>Strategy:</strong> Block KIT</td>
<td><strong>Strategy:</strong> Block KIT Block tumor blood vessel growth</td>
</tr>
<tr>
<td><strong>NCT #:</strong> NCT00764595</td>
<td><strong>NCT #:</strong> NCT00324987</td>
</tr>
<tr>
<td><strong>Contact:</strong> See site contact info below</td>
<td><strong>Contact:</strong> See each trial site.</td>
</tr>
</tbody>
</table>

**Surgery**

*Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor*

| Phase: 2 | **Iowa Oncology Research Association - CCOP** Des Moines, IA USA 515-244-7586 Roscoe F. Morton, MD |
| Stage: All | **University of Chicago** Chicago, IL USA Clinical Trials Office, 773-834-7424 Hedy Kindler, MD |
| Conditions: Gastrointestinal Stromal Tumor | **Wichita - CCOP** Wichita, KS USA 316-262-4467 Shaker R. Dakhlil, MD |
| Drug Type: Surgery | **Michigan Cancer Research Consortium == CCOP** Ann Arbor, MI USA 734-434-4930 Phillip J. Stella, MD |
| Strategy: Surgery | |
| **NCT #:** NCT00769782 | **Contact:** See site contact info below |
| **Niigata University Medical and Dental School** Niigata, Japan 81-25-227-2228 Tatsuo Kanda, MD |

**Kalamazoo - CCOP** Kalamazoo, MI USA 269-373-7458 Raymond S. Lord, MD
**Metro Minnesota - CCOP** St. Louis Park, MN USA 592-993-1517 Patrick J. Flynn, MD
**Ozarks Regional - CCOP** Springfield, MO USA 417-269-4520 John W. Goodwin, MD
**University of Mississippi Cancer Clinic** Jackson, MS USA Robert D. Hamilton 601-984-5590
**Montana Cancer Consortium - CCOP** Billings, MT USA 406-238-6290 Benjamin Marchello, MD
**Southeast Cancer Control Consortium - CCOP** Winston-Salem, NC USA 910-777-3036 James M. Atkins, MD
**Roswell Park Cancer Institute** Buffalo, NY USA Clinical Trials Office 877-275-7724
**Syracuse Hematology-Oncology Associate of Central New York - CCOP** East Syracuse, NY USA 315-472-7504 Jeffrey J. Kirshner, MD
**Columbus - CCOP** Columbus, OH USA 614-443-2267 Philip J. Kuebler, MD
**Dayton Clinical Oncology Program - CCOP** Kettering, OH USA 937-395-8678 Howard M Gross, MD
**Toledo Community Hospital Oncology - CCOP** Toledo, OH USA 419-255-5433 Paul L. Schaefer, MD
Masitinib, (AB1010)
Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour

Phase: 3
Stage: First-line
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFRA inhibitor
Strategy: Block KIT
NCT #: NCT00812240
Contact: Centre Oscar Lambret
Antoine Adenis, M.D.
a-adenis@o-lambret.fr
+33 (0) 3 20 29 59 59

Hospital Jean Minjoz
Besancon, France

Institut Bergonie
Bordeaux, France
Binh Bui Nguyen, MD

Centre Georges Francois Leclerc
Dijon, France

Centre Hospitalier Victor Jousselin
Dreux, France

Centre Oscar Lambret - Lille
Lille, France
Antoine Adenis, MD

Centre Leon Berard
Lyon, France
+33607507064
blay@lyon.fnclcc.fr
Jean Yves-Blay, MD, PhD

Institut Paoli Calmette
Marseille, France
Patrice Viens, MD, PhD

Centre Val d'Aurele
Montpellier, France

Centre Rene Gaudicheau
Nantes, France

Hopital Robert Debre
Reims, France

Hopital Charles Nicolle
Rouen, France

Centre Rene Huguenin
Saint-Cloud, France

Hopital Saint-Georges
Beirut, Lebanon

American University Hospital
Beirut, Lebanon

Middle East Institute of Health
Bsalim, Lebanon

Hopital Saint-Joseph
Dora, Lebanon

Hamoud Hospital
Saida, Lebanon

MD Anderson - Orlando
Orlando, FL USA
Clinical Trials Office - M.D. Anderson Cancer Center,
713-792-3245
Jon Trent, MD, PhD

Henry Ford Health System
Detroit, MI USA

Beth Israel Medical Center
New York, NY USA
Nilotinib or Imatinib
Phase III, Open-Label Study of
Nilotinib Versus Imatinib in GIST Patients

**Phase:** 3
**Stage:** First-line
**Conditions:** Gastrointestinal Stromal Tumor
**Drug Type:** KIT/PDGFRα inhibitor
**Strategy:** Block KIT

**NCT #:** NCT00785785
**Contact:** Novartis Pharmaceuticals
- +1-800-340-6843

**Universitätsklinik f. Innere Medizin Onkologische Ambulanz**
Innsbruck, Austria
- +43 512 504 23333
  - annaliege.gaechter@uki.at
- Eisterer Wolfgang, MD
- Thomas Brodowicz, MD
  - +43-40400-4466
  - +43-40400-4685

**Hotel Dieu du Quebec**
Quebec, Canada
- +1-418-691-2950
  - Felix Couture, MD
  - +1-418-691-5225
  - Felix Couture, MD

**Mount Sinai Hospital**
Toronto, ON Canada
- Martin Blackstein, MD
  - 011-416-586-5371
- Martin Blackstein, MD

**Ottawa Regional Cancer Center University of Ottawa**
Ottawa, Ontario Canada
- Tim Asmis, MD
  - 613-737-7700 ext 70316
  - Tim Asmis, MD

**Maisonneuve-Rosemont Hospital**
Montreal, QC Canada
- Lucas Sideris, MD
  - 514-252-3400 ext 4670

**CHUM - Hopital Notre-Dame**
Montreal, Quebec Canada
- Denis Soulieres, MD

**CHUS - Hospital Fleurimont**
Sherbrooke, Quebec Canada
- Brigitte Jean
- Rami Kobb, MD

**Aichi Cancer Center Hospital**
Aichi, Japan
- Akira Sawaki, MD
  - +81-52-762-6111
  - jutaku_a@aiicnc.jc.jp
- Akira Sawaki, MD

**National Cancer Center Hospital East**
Chiba, Japan
- Toshimasa Doi, MD
  - +81-4-7133-1111
  - todi@east.ncc.go.jp
- Toshimasa Doi, MD

**Hokkaido University Hospital**
Hokkaido, Japan
- Yoshito Komatsu
  - +81-11-706-5657
  - Yoshito Komatsu, MD

**Kumamoto University Hospital**
Kumamoto, Japan
- Haruhiko Cho, MD
  - +81-4-762-6111
  - hdobaba@kumamoto-u.ac.jp
- Hido Baba, MD

**Niigata University Medical and Dental School**
Niigata, Japan
- Tatsuo Kanda, MD
  - +81-25-227-0372
  - kandat@med.niigata-u.ac.jp
- Tatsuo Kanda, MD

**Osaka University Hospital**
Osaka, Japan
- Toshihiko Onozawa, MD
  - +81-5-989-5222
  - y.onozawa@scchr.jp
  - Wousuke Onozawa, MD

**Shizouka Cancer Center**
Shizuoka, Japan
- Yusuke Onozawa
  - +81-55-989-5222
  - y.onozawa@scchr.jp
  - Yusuke Onozawa, MD

**National Cancer Center Hospital**
Tokyo, Japan
- Yasuhide Yamada, MD
  - +81 33 542 5111
  - yamada@ncc.go.jp
- Yasuhide Yamada, MD

**Consorcio Hospitalari Parc Taulí**
Barcelona, Spain
- Jose G. Ruiz
  - +34-937-242-579
  - jgarciar@tauli.cat
- Charles Pericay, MD

**University Hospital La Paz**
Madrid, Spain
- Cristobal Belda-Iniesta, MD
  - 34-1-2071138
  - cebelda.hulp@salud.madrid.org
- Cristobal Belda-Iniesta, MD

**Chulalongkorn University**
Bangkok, Thailand
- Virose Sriuranpong, MD
  - +66-2-256-4533
  - vsrmutc40@gmail.com
- Virose Sriuranpong, MD

**Siriraj Hospital**
Bangkok, Thailand
- Vichien Srimuninnimit, MD
  - +66-2-419-4488
  - vvsrimuninnimit@gmail.com

**Vichien Srimuninnimit, MD**

**Prince of Songkla University**
Songkla, Thailand
- Patrapipt Sunpawaravong, MD
  - +66-74-451-469
  - spatrapia@medicine.psu.ac.th
  - Patrapipt Sunpawaravong, MD

**City of Hope**
Duarte, CA USA
- Neeti Arora
  - 626-256-4673 xt 63019
  - narora@coh.org
- Warren Chow, MD
Dasatinib (BMS-354825)

*Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors*

| Phase: 2 |
| Stage: First-line |
| Conditions: Gastrointestinal Stromal Tumor |
| Drug Type: KIT/PDGFRA inhibitor + SRC inhibitor |
| Strategy: Block KIT + Block KIT |
| NCT #: NCT00568750 |
| Contact: See site contact info below |

**Centre Hospitaleir Universitaire Vaudois**

Lausanne, Switzerland
41-21-314-0150
Michael Montemurro, MD

---

Nilotinib

*Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)*

| Phase: 2 |
| Stage: First-line |
| Conditions: Gastrointestinal Stromal Tumor |
| Drug Type: KIT/PDGFRA inhibitor |
| Strategy: Block KIT |
| NCT #: NCT00756509 |
| Contact: Novartis Basel + 41 61 324 1111 |

**Site name unknown, Bad Saarow**

Bad Saarow, Germany

---

**Sunitinib**

*Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant*

| Phase: 4 |
| Stage: Gleevec-resistant |
| Conditions: Gastrointestinal Stromal Tumor |
| Drug Type: KIT/PDGFRA inhibitor |
| Strategy: Block KIT |
| NCT #: NCT00793871 |
| Contact: Pfizer Oncology Clinical Trial Information Service 1-877-369-9753 PfizerCancerTrials@emergin gmed.com Pfizer CT.gov Call Center 1-800-718-1021 |

**Site name unknown Beijing 100035**

Beijing, China

**Site name unknown Beijing 100071**

Beijing, China

**Site name unknown, Beijing 100021**

Beijing, China

**Site name unknown, Nanjing 210002**

Nanjing, Jiangsu China

---

**Site name unknown, Milan**

Milan, Italy

---

**Site name unknown, Bad Saarow**

Bad Saarow, Germany
**Sunitinib or Imatinib**  
*Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg)*

- **Phase:** 3  
- **Stage:** Gleevec-resistant  
- **Conditions:** Gastrointestinal Stromal Tumor  
- **Drug Type:** KIT/PDGFRα inhibitor  
- **Strategy:** Block KIT  
- **NCT #:** NCT00372567  
- **Contact:** Pfizer Oncology Clinical Trial Information Service  
  1-877-369-9753  
  PfizerCancerTrials@emergin gmed.com  
  1-800-718-1021

  - **Site name unknown, Marseille, France 13385**  
  - **Marseille, France**

  - **Site name unknown, Goettingen 37075**  
  - **Goettingen, Germany**

  - **Site name unknown, Hamburg 22767**  
  - **Hamburg, Germany**

- **Southwest German Cancer Center at Eberhard-Karls University**  
  Tuebingen, Germany  
  49-707-1298-2127  
  joerg.hartmann@med.uni-tuebingen.de  
  Joerg T. Hartmann, MD

- **Site name unknown, Hong Kong, 0**  
  - **Hong Kong, Hong Kong**

- **Site name unknown, Lai Chi Kok 0**  
  - **Lai Chi Kok, Kowloon Hong Kong SAR**

- **Site name unknown, Tuen Mun 0**  
  - **Tuen Mun, New Territories Hong Kong SAR**

- **Site name unknown, Bologna 40138**  
  - **Bologna, Italy**

---

**BIIB021 (CNF2024)**  
*An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors*

- **Phase:** 2  
- **Stage:** Gleevec-resistant  
- **Conditions:** Gastrointestinal Stromal Tumor  
- **Drug Type:** HSP90 inhibitor  
- **Strategy:** Destroy KIT  
- **NCT #:** NCT00618319  
- **Contact:** Biogen Idec oncologyclinicaltrials@biogen idec.com

  - **Site name unknown, Henderson 89074**  
  - **Henderson, NV USA**

  - **Site name unknown, Las Vegas 89102**  
  - **Las Vegas, NV USA**

  - **Site name unknown, Las Vegas 89106**  
  - **Las Vegas, NV USA**

  - **Site name unknown, Las Vegas 89148**  
  - **Las Vegas, NV USA**

  - **Cleveland Clinic Taussig Cancer Center**  
  - **Cleveland, OH USA**

  - **Fox Chase Cancer Center**  
  - **Philadelphia, PA USA**  
  - **1-888-FOX-CHASE**  
  - **Margaret von Mehren, M.D.**

  - **Royal Marsden Hospital**  
  - **London, UK**

  - **Site name unknown, London NW1 2PG**  
  - **London, UK**

  - **Site name unknown, London W1**  
  - **London, UK**

- **Christie Hospital NHS Trust**  
  - **Manchester, Lancashire UK**

- **Karmanos Cancer Institute**  
  - **Detroit, MI USA**  
  - **all (800) KARMANOS (1 -800-527-6266) or e-mail info@karmanos.org**  
  - **Anthony Shields, MD**

- **Site name unknown, Farmington Hills 48334**  
  - **Farmington Hills, MI USA**

  - **Memorial Sloan-Kettering Cancer Center**  
  - **New York, NY USA**  
  - **Robert Maki, MD**
### Nilotinib

**Nilotinib in Advanced GIST**

<table>
<thead>
<tr>
<th>Phase: 2</th>
<th>Stage: Gleevec-resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions: Gastrointestinal Stromal Tumor</td>
<td></td>
</tr>
<tr>
<td>Drug Type: KIT/PDGFRA inhibitor</td>
<td></td>
</tr>
<tr>
<td>Strategy: Block KIT</td>
<td></td>
</tr>
<tr>
<td>NCT #: NCT00782834</td>
<td></td>
</tr>
<tr>
<td>Contact: See site contact info below</td>
<td></td>
</tr>
</tbody>
</table>

**Fox Chase Cancer Center**
Philadelphia, PA USA
1-888-FOX-CHASE (369-2427)
Margaret von Mehren, M.D.

### Sorafenib (Nexavar, BAY 43-9006)

**Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With**

<table>
<thead>
<tr>
<th>Phase: 2</th>
<th>Stage: Gleevec-resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions: Gastrointestinal Stromal Tumor</td>
<td></td>
</tr>
<tr>
<td>Drug Type: KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI) + RAF inhibitor</td>
<td></td>
</tr>
<tr>
<td>Strategy: Block KIT + Block KIT Signal Path</td>
<td></td>
</tr>
<tr>
<td>NCT #: NCT00265798</td>
<td></td>
</tr>
<tr>
<td>Contact: Clinical Trials Office - University of Chicago Cancer Research 773-834-7424</td>
<td></td>
</tr>
</tbody>
</table>

**University of Chicago**
Chicago, IL USA
Clinical Trials Office, 773-834-7424
Hedy Kindler, MD

### Imatinib + Sunitinib

**Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors**

<table>
<thead>
<tr>
<th>Phase: 1</th>
<th>Stage: Gleevec-resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions: Gastrointestinal Stromal Tumor</td>
<td></td>
</tr>
<tr>
<td>Drug Type: KIT/PDGFRA inhibitor</td>
<td></td>
</tr>
<tr>
<td>Strategy: Block KIT</td>
<td></td>
</tr>
<tr>
<td>NCT #: NCT00573404</td>
<td></td>
</tr>
</tbody>
</table>
| Contact: Vanderbilt-Ingram Cancer Center |}

### Dasatinib (BMS-354825)

**Trial of Dasatinib in Advanced Sarcomas**

<table>
<thead>
<tr>
<th>Phase: 2</th>
<th>Stage: Gleevec-resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions: Gastrointestinal Stromal Tumor</td>
<td></td>
</tr>
<tr>
<td>Drug Type: KIT/PDGFRA inhibitor + SRC inhibitor</td>
<td></td>
</tr>
<tr>
<td>Strategy: Block KIT + Block KIT Signal Path</td>
<td></td>
</tr>
<tr>
<td>NCT #: NCT00464620</td>
<td></td>
</tr>
<tr>
<td>Contact: Kathleen Granlund <a href="mailto:kegranlund@sarctrials.org">kegranlund@sarctrials.org</a> 734-930-7607</td>
<td></td>
</tr>
</tbody>
</table>

**Arkansas Children's Hospital**
Little Rock, AR USA
Bryce Warren
WarrenBryceA@uams.edu
Kimo Stine

**City of Hope**
Duarte, CA USA
Neeti Arora
626-256-4673 ext. 63019
NArora@coh.org
Warren Chow, MD

### Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

<table>
<thead>
<tr>
<th>Phase: 4</th>
<th>Stage: Gleevec-resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions: Gastrointestinal Stromal Tumor</td>
<td></td>
</tr>
<tr>
<td>Drug Type: VEGFR inhibitor (TKI)</td>
<td></td>
</tr>
<tr>
<td>Strategy: Block tumor blood vessel growth</td>
<td></td>
</tr>
<tr>
<td>NCT #: NCT00777504</td>
<td></td>
</tr>
<tr>
<td>Contact: See site contact info below</td>
<td></td>
</tr>
</tbody>
</table>

**University Medical Center Nijmegen st Raboud**
Nijmegen, Gelderland Netherlands
31 24 3610353
c.vanherpen@onco.umcn.nl

**C.M.L van Herpen, Md, Phd**
**Everolimus**

**Treatment of Patients With RAD001 Who Have Progressive Sarcoma**

- **Phase:** 2
- **Stage:** Gleevec-resistant
- **Conditions:** Sarcoma
- **Drug Type:** mTOR inhibitor
- **Strategy:** Block KIT Signal Path
- **NCT #:** NCT00767819
- **Contact:** Novartis Pharmaceuticals
  +1 800-340-6843

**Site name unknown, Berlin**

Berlin, Germany

**Site name unknown, Dusseldorf**

Dusseldorf, Germany

**Site name unknown, Mannheim**

Mannheim, Germany

**Site name unknown, Munich**

Munchen, Germany

**Site name unknown, Milan**

Milan, Italy
Doxorubicin + Flavopiridol

Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

Phase: 1
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: Transcription inhibitor + Chemotherapy
Strategy: Freeze the cell division cycle
NCT #: NCT00098579
Contact: See site contact info below

Memorial Sloan-Kettering Cancer Center
New York, NY USA
212-639-7573
dadamod@mskcc.org
David D’Adamo, MD, PhD,

Imatinib + IL-2

Imatinib + IL-2

Phase: 1
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT inhibitor + Immune stimulate
Strategy: Block KIT + Stimulate the immune system
NCT #: NCT00090879

Contact: See site contact info below

Institut Gustave-Roussy
Villejuif Cedex, France
Patricia Pautier, MD
33 (0) 1 42 11 42 11
pautier@igr.fr
Laurence Zitvogel, MD

Multi-bacteria vaccine (MBV)

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.

Phase: 1
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: Immune stimulate
Strategy: Stimulate the immune system
NCT #: NCT00623831
Contact: See site contact info below

Krankenhaus Nordwest
Frankfurt, Germany
Antje Neumann
neumann.antje@khnw.de
069 7601 4161
Elke Jaeger, MD

SF1126

A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K)

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: NCT00907205
Contact: See site contact info below

TGen Clinical Research Services
Scottsdale, AZ USA
Cathy Costanza, RN, BS, OCN
480-323-1550
costanza@shc.org
Jennifer Privratsky
480-323-1591
jprivratsky@shc.org
Ramesh Ramanathan, MD

AUY922

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: NCT00526045
Contact: Novartis Pharmaceuticals
1 800 340-6843

Site Name unknown, Bellinzona
Bellinzona, Switzerland

David Geffen School of Medicine at UCLA
Los Angeles, CA USA
CBritten@mednet.ucla.edu
310-825-5268
Carolyn Britten, M.D.
Medical College of Georgia
Augusta, GA USA
706-721-2505
tsamuel@mcg.edu
Thomas Samuel, M.D.

Dana Farber Cancer Institute
Boston, MA USA
617 632-5053
stephen_hodi@dfci.harvard.edu
Stephen Hodi, MD, PhD

Washington University School of Medicine
St. Louis, MO USA
800-600-3606
info@ccadmin.wustl.edu
Timothy Pluard, MD

Nevada Cancer Institute
Las Vegas, NV USA
(702) 822-5174
Nicholas Vogelzang, MD

MD Anderson Cancer Center
Houston, TX USA
800-392-1611 (in U.S.A.)
713-792-6161 (outside U.S. A.)
Jon Trent, MD, PhD

Cancer Therapy and Research Center
San Antonio, TX USA
210-450-5798
Francis Giles, MD

Dana Farber Cancer Institute
Boston, MA USA
Melissa Hohos
617 632-2201
mhohos@partners.org
George Demetri, MD, PhD

Massachusetts General Hospital
Boston, MA USA
617-726-6225
nisaac1@partners.org
Stephen Isakoff, MD

Nevada Cancer Institute
Las Vegas, NV USA
Dianna Tercan
(702) 822-5483
Lin-Chi Chen, M.D., Ph.D.

Cancer Therapy and Research Center
San Antonio, TX USA
Epp Goodwin
210-450-5798
Francis Giles, MD

SNX-5422
SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: HSP90 inhibitor
- Strategy: Destroy KIT
- NCT #: NCT00644072
- Contact: Warren Grant Magnuson Clinical Center
  Bethesda, MD USA
  Clinical Trials Office
  888-NCI-1937
  Giuseppe Giaccone, MD, PhD

Vorinostat + Bortezomib
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: HDAC inhibitor + Proteasome inhibitor
- Strategy: Inhibit protein translation + Unblock cell death genes
- NCT #: NCT00227513
- Contact: Carbone Cancer Center, University of Wisconsin
  Madison, WI USA
  Clinical Trials Office
  608-262-5223
  George Wilding, MD

---

**BGT226**

*A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer*

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: mTOR inhibitor
- Drug Type: PI3K inhibitor
- Strategy: Block KIT Signal Path
- NCT #: NCT00600275
- Contact: Novartis
  800 340-6843

Princess Margaret Hospital
Toronto, ON Canada
Lillian Siu, M.D.

Hospital Vall d'Hebron
Barcelona, Spain

**MP470**

*Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470,*

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: KIT/PDGFRα inhibitor
- Strategy: Block KIT
- NCT #: NCT00894894
- Contact: SuperGen
  Gil Fine, PhD
  925-560-0100
gfine@supergen.com
  Angelique Mittan, CLS
  925-560-0100

**SNX-5422**

*SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment*

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: HSP90 inhibitor
- Strategy: Destroy KIT
- NCT #: NCT00644072
- Contact: Warren Grant Magnuson Clinical Center
  Bethesda, MD USA
  Clinical Trials Office
  888-NCI-1937
  Giuseppe Giaccone, MD, PhD

**Vorinostat + Bortezomib**

*Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors*

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: HDAC inhibitor + Proteasome inhibitor
- Strategy: Inhibit protein translation + Unblock cell death genes
- NCT #: NCT00227513
- Contact: Carbone Cancer Center, University of Wisconsin
  Madison, WI USA
  Clinical Trials Office
  608-262-5223
  George Wilding, MD

---

**BGT226**

*A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer*

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: mTOR inhibitor
- Drug Type: PI3K inhibitor
- Strategy: Block KIT Signal Path
- NCT #: NCT00600275
- Contact: Novartis
  800 340-6843

Princess Margaret Hospital
Toronto, ON Canada
Lillian Siu, M.D.

Hospital Vall d'Hebron
Barcelona, Spain

**MP470**

*Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470,*

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: KIT/PDGFRα inhibitor
- Strategy: Block KIT
- NCT #: NCT00894894
- Contact: SuperGen
  Gil Fine, PhD
  925-560-0100
gfine@supergen.com
  Angelique Mittan, CLS
  925-560-0100

**SNX-5422**

*SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment*

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: HSP90 inhibitor
- Strategy: Destroy KIT
- NCT #: NCT00644072
- Contact: Warren Grant Magnuson Clinical Center
  Bethesda, MD USA
  Clinical Trials Office
  888-NCI-1937
  Giuseppe Giaccone, MD, PhD

**Vorinostat + Bortezomib**

*Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors*

- Phase: 1
- Stage: Gleevec-resistant
- Conditions: Solid Tumors
- Drug Type: HDAC inhibitor + Proteasome inhibitor
- Strategy: Inhibit protein translation + Unblock cell death genes
- NCT #: NCT00227513
- Contact: Carbone Cancer Center, University of Wisconsin
  Madison, WI USA
  Clinical Trials Office
  608-262-5223
  George Wilding, MD

---
AMG 479 + AMG 655

**AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors**

- **Phase:** 2
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** IGF1R inhibitor + TNF Inhibitor
- **Strategy:** Block related tumor signal paths

- **NCT #:** NCT00819169
- **Contact:** Amgen Call Center 866-572-6436

Site name unknown, Barcelona 08036
Barcelona, Spain

Site name unknown, Santa Monica 90403
Santa Monica, CA USA

University of Chicago
Chicago, IL USA
Clinical Trials Office, 773-834-7424
Hedy Kindler, MD

Site name unknown, Indianapolis
Indianapolis, IN USA

Site name unknown, Detroit
Detroit, MI USA

---

AT13387

**Phase 1 Study of HSP90 inhibitor AT13387 in solid tumors**

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** HSP90 inhibitor
- **Strategy:** Destroy KIT

- **NCT #:** NCT00878423
- **Contact:** Andrew Wolanski 617-632-6623
Andrew_Wolanski@dfci.harvard.edu

Beth Israel Deaconess Medical Center
Boston, MA USA
Sue Gotheardt RN, OCN (617) 632-9272
Bruce Dezube M.D.

Massachusetts General Hospital
Boston, MA USA
Eunice Kwak, MD

Dana Farber Cancer Institute
Boston, MA USA
Geoffrey Shapiro, MD, PhD

---

BEZ235

**A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer**

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** mTOR inhibitor
PI3K inhibitor
Strategy: Block KIT Signal Path

- **NCT #:** NCT00620594
- **Contact:** Novartis 862-778-8300

Nevada Cancer Institute
Las Vegas, NV USA
Dianna Tercan (702) 822-5483
Wolfram Samlowski, M.D.

Sarah Cannon Research Institute
Nashville, TN USA
615-329-7274
hburriss@tnonc.com
Howard A. Burris, III MD

---

BAY 73-4506

**Phase I study of BAY 73-4506**

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** KIT/PDGFRA inhibitor
VEGFR inhibitor (TKI)
Strategy: Block KIT

- **NCT #:** See site contact info below
- **Contact:** MD Anderson Cancer Center
Houston, TX USA
Clinical Trials Office 713-792-3245
Jon Trent, MD, PhD

South Texas Accelerated Research Therapeutics (START)
San Antonio, TX USA
Tracy Dufresne, RN 210-593-5265
tracy.dufresne@start.stoh.com

---

BIIB021 (CNF2024)

**Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors**

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** HSP90 inhibitor
Strategy: Destroy KIT

- **NCT #:** NCT00618735
- **Contact:** Biogen Idec oncologyclinicaltrials@biogenidec.com

Premier Oncology, Santa Monica
Santa Monica, CA USA

South Texas Accelerated Research Therapeutics (START)
San Antonio, TX USA
**Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors**

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** IGF1R inhibitor  
**Strategy:** Block related tumor signal paths  
**NCT #:** NCT00555724  
**Contact:** Biogen Idec  
 oncologyclinicaltrials@biogenidec.com

**Site name unknown, Los Angeles, CA**  
Los Angeles, CA USA

**University of Colorado**  
Aurora, CO USA  
Sarah Eppers  
720-848-0052  
SARAH.EPPERS@ucdenver.edu  
Stephen Leong

**Fox Chase Cancer Center**  
Philadelphia, PA USA  
Kathleen Lear, RN, OCN, CCRP  
Phone: 215-214-1511  
Email: kathleen.lear@fccc.edu  
Roger Cohen, MD

---

**A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule**

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** PI3K inhibitor  
**Strategy:** Block KIT Signal Path  
**NCT #:**  
**Contact:** See site contact info below

**Sarah Cannon Research Institute**  
Nashville, TN USA  
615-329-SCRI (7274)

---

**Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors**

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** IGF1R inhibitor  
**Strategy:** Block related tumor signal paths  
**NCT #:** NCT00569036  
**Contact:** For site information outside the USA please email:  
Clinical.Trials@bms.com  
First line of email MUST contain NCT# & Site#.  

**Site name unknown, East Melbourne**  
East Melbourne, Australia  
Site # 003

**Site name unknown, Footscray, Australia**  
Footscray, Victoria Australia  
Site # 004

**Site name unknown, Heidelberg Australia**  
Heidelberg, Victoria Australia  
Site # 002

**Site name unknown, Parkville, Australia**  
Parkville, Victoria Australia  
Site #001

---

**Cixutumumab + Temsirolimus**

**Cixutumumab and Temsirolimus in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment**

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** IGF1R inhibitor + mTOR Inhibitor  
**Strategy:** Block related tumor signal paths  
**NCT #:** NCT00880282  
**Contact:**

**Children's Hospital of Orange County**  
Orange, CA USA  
Violet Shen  
714-532-8636

**Children's National Medical Center**  
Washington, DC USA  
Clinical Trials Office  
202-884-2549

**Masonic Cancer Center at University of Minnesota**  
Minneapolis, MN USA  
Clinical Trials Office  
612-624-2620

**Cincinnati Children's Hospital Medical Center**  
Cincinnati, OH USA  
Clinical Trials Office  
513-636-2799
**GDC-0941**

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Is Insufficient

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: NCT00876109
Contact: See site contact info below

TGen Clinical Research Services
Scottsdale, AZ USA
Lyne Hull
480-323-1071
LHull@SHC.org
Daniel D. Hoff, MD

Dana Farber Cancer Institute
Boston, MA USA
Melissa Hohos
617 632-2201
mighthos@partners.org
George Demetri, MD, PhD

Karmanos Cancer Institute
Detroit, MI USA
Jie Zhang
313-576-9365
zhangj@karmanos.org

**IMC-A12 + CCI-779**

IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor + mTOR Inhibitor
Strategy: Block related tumor signal paths
NCT #: NCT00678769
Contact: Aung Naing, MD
713-563-0181

Karmanos Cancer Institute
Detroit, MI USA
all (800) KARMANOS (1-800-527-6266) or e-mail info@karmanos.org.

MD Anderson Cancer Center
Houston, TX USA
713-563-0181
Aung Naing, MD

**IMC-A12 + CCI-779**

Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor + mTOR Inhibitor
Strategy: Block related tumor signal paths
NCT #: NCT00678223
Contact: Aung Naing, MD
713-563-0181

MD Anderson Cancer Center
Houston, TX USA
713-563-0181
Aung Naing, MD

**IPI-493**

A Phase I Dose Escalation Study of IPI-493

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: NCT00724425
Contact: See site contact info below

Premier Oncology, Scottsdale
Scottsdale, AZ USA
Patricia Shannon, RN
480 860-5000 xt 223
pshannon@premiereoncology.com
David Mendelson, M.D.

San Diego Pacific Oncology and Hematology Associates
Encinitas, CA USA
Karen Brady, RN MSN
760-752-3340
kbrady@premiereoncology.com
Richard Just, M.D.

Premier Oncology, Santa Monica
Santa Monica, CA USA
Marilyn Mulay, NP
310-633-8400
mmulay@premiereoncology.com

University of Colorado
Aurora, CO USA
Stacy Grolnic, RN
720-848-0655
stacy.grolnic@uchsc.edu

Mary Crowley Medical Research Center (Central Office)
Dallas, TX USA
Kay Easterwood-Sanchez
214-658-1943

Lee Rosen M.D.
**KW2450**

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** IGF1R inhibitor
- **Strategy:** Block related tumor signal paths
- **NCT #:** NCT00921336
- **Contact:**
  - Danyel Davis
  - (609) 919-1100
ddavis@kyowa-kirin-pharma.com
  - Niranjan Rao
  - (609) 919-1100
nrao@kyowa-kirin-pharma.com

Memorial Sloan-Kettering Cancer Center
New York, NY USA

**MEDI-573**

A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** IGF1R inhibitor
- **Strategy:** Block related tumor signal paths
- **NCT #:** NCT00816361
- **Contact:**
  - Jill Schmidt
  - 301-398-0000
  - schmidtj@medimmune.com
  - Lorena DeRienzo
  - 301-398-0000
de-rienzol@medimmune.com

Mayo Clinic, Jacksonville
Jacksonville, FL USA
Michele Maharaj
904-953-6136
maharaj.michele@mayo.edu
Michael E. Menefee, MD

**OSI-906**

Phase 1 Study of Continuous OSI -906 Dosing

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** IGF1R inhibitor
- **Strategy:** Block related tumor signal paths
- **NCT #:** NCT00514007
- **Contact:**
  - Jill Schmidt
  - 301-398-0000
  - schmidtj@medimmune.com
  - Lorena DeRienzo
  - 301-398-0000
de-rienzol@medimmune.com

Beaton West of Scotland Cancer Centre
Glasgow, UK

**PX-478**

Phase 1 Trial of PX-478

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** HIF-1α inhibitor
- **Strategy:** Block related tumor signal paths
- **Strategy:** Block tumor blood vessel
- **NCT #:** NCT00522652
- **Contact:** See site contact info below

TGen Clinical Research Services
Scottsdale, AZ USA
Lynne Hull
480-323-1071
lhull@shc.org
Daniel D. VonHoff, MD

MD Anderson Cancer Center
Houston, TX USA
Hala Abdulkadir
713-792-9944
habdulka@mdanderson.org
Roy S. Herbst, PhD
**PX-866**

*Phase I Trial of Oral PX-866*

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage:</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>PI3K inhibitor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT Signal Path</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00726583</td>
</tr>
<tr>
<td>Contact:</td>
<td>See site contact info below</td>
</tr>
</tbody>
</table>

**University of Colorado**

Aurora, CO USA

| Sharon hecker |
| 720-848-0667 |
| sharon.hecker@ucdenver.edu |

**MD Anderson Cancer Center**

Houston, TX USA

| Antonio Jimeno, MD |
| 713-563-3559 |
| rclement@mdanderson.org |

**R1507**

*A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors*

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage:</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>IGF1R inhibitor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block related tumor signal paths</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00560144</td>
</tr>
<tr>
<td>Contact:</td>
<td>Hoffmann-La Roche</td>
</tr>
<tr>
<td>Please reference Study ID Number: NO21200</td>
<td></td>
</tr>
<tr>
<td>973-235-5000</td>
<td></td>
</tr>
<tr>
<td>800-526-6367 (US only)</td>
<td></td>
</tr>
</tbody>
</table>

**Site name unknown, Denver 80218**

Denver, CO USA

**Site name unknown, Bethesda 20982**

Bethesda, MD USA

**Memorial Sloan-Kettering Cancer Center**

New York, NY USA

| 212-639-8267 |
| Dr. Tanya Trippett |

**SNX-5422**

*Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas*

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage:</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>HSP90 inhibitor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Destroy KIT</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00647764</td>
</tr>
<tr>
<td>Contact:</td>
<td>Pfizer Oncology Clinical Trial Information Service</td>
</tr>
<tr>
<td>1-877-369-9753</td>
<td></td>
</tr>
<tr>
<td><a href="mailto:PfizerCancerTrials@emerginmed.com">PfizerCancerTrials@emerginmed.com</a></td>
<td></td>
</tr>
<tr>
<td>Pfizer CT.gov Call Center</td>
<td></td>
</tr>
<tr>
<td>1-800-718-1021</td>
<td></td>
</tr>
</tbody>
</table>

**Site name unknown, Bethesda 20982**

Bethesda, MD USA

**SNX-5422**

*Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies*

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage:</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>HSP90 inhibitor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Destroy KIT</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00506805</td>
</tr>
<tr>
<td>Contact:</td>
<td>Pfizer Oncology Clinical Trial Information</td>
</tr>
<tr>
<td>1-877-369-9753</td>
<td></td>
</tr>
<tr>
<td><a href="mailto:PfizerCancerTrials@emerginmed.com">PfizerCancerTrials@emerginmed.com</a></td>
<td></td>
</tr>
<tr>
<td>Pfizer CT.gov Call Center</td>
<td></td>
</tr>
<tr>
<td>1-800-718-1021</td>
<td></td>
</tr>
</tbody>
</table>

**TGen Clinical Research Services**

Scottsdale, AZ USA

| Joyce Ingold RN |
| 480-323-1339 |
| jingold@shc.org |
| Daniel D. Von Hoff, MD |

**Sarah Cannon Research Institute**

Nashville, TN USA

| Jessica Gilbert |
| 615 329-7238 |
| Howard A. Burris, III MD |

**Sorafenib + Vorinostat**

*Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors*

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage:</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>HDAC inhibitor + KIT/PDGFRA inhibitor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT + Unblock cell death genes + Destroy KIT</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00635791</td>
</tr>
<tr>
<td>Contact:</td>
<td>See site contact info below</td>
</tr>
</tbody>
</table>

**University of Colorado**

Aurora, CO USA

| Stacy Grolnic |
| 720-848-0655 |
| stacy.grolnic@uchsc.edu |

**Howard A. Burris, III MD**

**Sarah Cannon Research Institute**

Nashville, TN USA

| Jessica Gilbert |
| 615 329-7238 |
| Howard A. Burris, III MD |

**University of Pennsylvania**

Philadelphia, PA USA

| David Ross Camidge MD |
| 16 |
### STA-9090
*Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** HSP90 inhibitor
- **Strategy:** Destroy KIT
- **NCT #:** NCT00687934
- **Contact:** See site contact info below

**Premier Oncology, Santa Monica**
Santa Monica, CA USA
310-633-8400
Lee Rosen, MD

**US Oncology - Dayton**
Kettering, OH USA
robert.raju@usoncology.com
(937)293-1622
Robert Raju, MD

### STA-9090
*Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** HSP90 inhibitor
- **Strategy:** Destroy KIT
- **NCT #:** NCT00688116
- **Contact:** See site contact info below

**Dana Farber Cancer Institute**
Boston, MA USA
Pilar De La Roche Mur
617-632-5841

**Massachusetts General Hospital**
Boston, MA USA
Pilar De La Roche Mur
617-632-5841

**Beth Israel Deaconess Medical Center**
Boston, MA USA
Pilar De La Roche Mur
617-632-5841

### Sunitinib + CP-751,871
*Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** KIT/PGDFRA inhibitor + IGF1R inhibitor
- **Strategy:** Block KIT + Block related tumor signal paths
- **NCT #:** NCT00729833
- **Contact:** EmergingMed
  (877) 369-9753
  PfizerCancerTrials@emergin gmed.com
  Pfizer CT.gov Call Center
  1-800-718-1021

**Premier Oncology, Santa Monica**
Santa Monica, CA USA
310-633-8400
Lee Rosen

**South Texas Accelerated Research Therapeutics (START)**
San Antonio, TX USA

### XL147
*Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** PI3K inhibitor
- **Strategy:** Block KIT Signal Path
- **NCT #:** NCT00486135
- **Contact:** Exelixis Contact Line
  866-939-4041

**Hospital Vall d’Hebron**
Barcelona, Spain
Gemma Sala
+34 93 489 4158
gsala@vhebron.net
Jose Baselga, MD, PhD

**Dana Farber Cancer Institute**
Boston, MA USA
Pilar de la Rocha Mur
617-632-5841
pilar_DeLaRochaMur@dfci.harvard.edu
Geoffrey Shapiro, MD

**Mary Crowley Medical Research Center (Baylor)**
Dallas, TX USA
J.R. Dolan
214-658-1943
Gerald Edelman MD, PhD

### XL228
*Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** IGF1R inhibitor
- **Strategy:** Block related tumor signal paths
- **NCT #:** NCT00526838
- **Contact:** Exelixis Contact Line
  1-866-939-4041

**UCLA’s Jonsson Comprehensive Cancer Center**
Los Angeles, CA USA
Lisa Yonemoto
310-825-4477
Carolyn Britten, MD
### Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors

**XL765**

#### Radiation

**Radiation Therapy as Palliative Treatment of GIST (GIST-RT)**

- **Phase:** 1
- **Stage:** Palliative
- **Conditions:** Gastrointestinal Stromal Tumor
- **Drug Type:** None
- **Strategy:** Radiation
- **NCT #:** NCT00515931
- **Contact:** See site contact info below

**Helsinki University Central Hospital**
Helsinki, Finland
947173208 Ext. 358
heikki.joensuu@hus.fi
Heikki Joensuu, MD

---

**Sunitinib + Radiation**

**Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer**

- **Phase:** 2
- **Stage:** Palliative
- **Conditions:** Any type of Cancer
- **Drug Type:** KIT/PDGFRα inhibitor
- **Strategy:** Block KIT
- **NCT #:** NCT00463060
- **Contact:** See site contact info below

**Mount Sinai School of Medicine**
New York, NY USA
212-241-7503
johnny.kao@mountsinai.org
Johnny Kao, MD

---

**Imatinib**

*A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor*

- **Phase:** 3
- **Stage:** Stable Disease
- **Conditions:** Gastrointestinal Stromal Tumor
- **Drug Type:** KIT/PDGFRα inhibitor
- **Strategy:** Block KIT
- **NCT #:** See site contact info below

**Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital**
Amsterdam, Netherlands